331
Participants
Start Date
April 3, 2023
Primary Completion Date
January 17, 2025
Study Completion Date
March 7, 2025
Cagrilintide
Participants will receive 2.4 mg cagrilintide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Semaglutide
Participants will receive 2.4 mg semaglutide s.c. OW after a dose escalation period of 16 weeks for 52 weeks
Placebo Semaglutide
Participants will receive placebo matched to semaglutide
National Taiwan University Hospital, Taipei
Seino Internal Medicine Clinic, Koriyama-shi
Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi
Heiwadai Hospital, Miyazaki
OCROM Clinic, Suita-shi
Yao Tokushukai General Hospital, Yao-shi
TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology, Aichi
The University of Tokyo Hospital, Diabetes and Metabolic, Bunkyo-ku, Tokyo
Akaicho Clinic, Chiba-shi, Chiba
Suidoubashi Medical Clinic, Chiyoda-ku, Tokyo
The Institute of Medical Science, Asahi Life Foundation, Chuo-ku, Tokyo
Okabe Clinic, Chuo-ku, Tokyo
Kawada Clinic, Gunma
Naka Kinen Clinic, Ibaraki
Iwate Medical University Uchimaru Medical Center, Division of Diabetes and Metabolism and Endocrine medicine, Numakunai
Osaka NISHI-UMEDA Clinic, Osaka
Shinsapporo Seiryou Hospital, General Clinical Department, Sapporo-shi, Hokkaido
Shinden Higashi Clinic, Sendai-shi, Miyagi
Tokyo-Eki Center-building Clinic, Tokyo
Fukuwa Clinic, Tokyo
ToCROM Clinic, Tokyo
Minamino Cardiovascular Hospital, Tokyo
Lead Sponsor
Novo Nordisk A/S
INDUSTRY